In the fast-evolving field of antibody–drug conjugates (ADCs), linker chemistry plays a decisive role in defining therapeutic performance. The ability to control the drug-to-antibody ratio (DAR), conjugation site, and overall molecular stability directly impacts both efficacy ...Learn More

Watertown, MA - June 29, 2025 - Biopharma PEG, a leading innovator in high-quality polyethylene glycol (PEG) derivatives, today announced it has successfully obtained Drug Master File (DMF) approval from the U.S. Food and Drug Administration (FDA) for its self-developed HZ-PEG-HZ ...Learn More

Antibody-drug conjugates (ADCs) combine potent small-molecule drugs with monoclonal antibodies for targeted cancer therapy. A major challenge is loading enough drug onto each antibody without compromising solubility or circulation time. Introducing polyethylene glycol (PEG) ...Learn More

SAN DIEGO, CA – April 29, 2025 – Biopharma PEG Scientific Inc., a leading provider of high-quality polyethylene glycol (PEG) derivatives, today announced its participation in TIDES USA 2025, taking place from May 19 - 22, 2025, at the Manchester Grand Hyatt San Diego. ...Learn More

Watertown, MA – March 24, 2025 – Biopharma PEG, a leading supplier of high-quality polyethylene glycol (PEG) derivatives, highlights its innovative product DSPE-PEG-Mannose, an advanced biomedical polymer with significant potential in drug delivery, tumor-targeted therapy, ...Learn More